Trademark/Service Mark Application, Principal Register
PTO- 1478
Approved for use through 10/31/2024. OMB 0651-0009
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number
Trademark/Service Mark Application, Principal Register
*DESCRIPTION OF THE MARK
(and Color Location, if applicable)
The mark consists of the word "BASILEA" surrounded by an oval.
PIXEL COUNT ACCEPTABLE
YES
PIXEL COUNT
711 x 250
REGISTER
Principal
APPLICANT INFORMATION
*OWNER OF MARK
Basilea Pharmaceutica International AG, Allschwil
*MAILING ADDRESS
Hegenheimermattweg 167b
*CITY
Allschwil
*COUNTRY/REGION/JURISDICTION/U.S. TERRITORY
Switzerland
*ZIP/POSTAL CODE
(Required for U.S. and certain international addresses)
4123
*EMAIL ADDRESS
XXXX
LEGAL ENTITY INFORMATION
TYPE
corporation
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY OF INCORPORATION
Switzerland
GOODS AND/OR SERVICES AND BASIS INFORMATION
INTERNATIONAL CLASS
001
*IDENTIFICATION
Chemical substances for use in the manufacture of pharmaceutical preparations for the treatment of dermatological conditions and for the
treatment of infections and diseases; chemical substances for use in research and development of pharmaceuticals for the treatment of dermatological conditions and for the treatment of infections and
diseases; diagnostic preparations for scientific clinical use; diagnostic reagents for clinical or medical laboratory use
FILING BASIS
SECTION 1(b)
INTERNATIONAL CLASS
005
*IDENTIFICATION
Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of dermatological conditions, namely,
eczema, inflammation, infection, warts, psoriasis, aging of the skin, ultra violet radiation and cancer; Pharmaceutical and veterinary products and preparations, namely, for the treatment and
prevention of infections caused by bacteria, fungi, viruses, and rheumatoid arthritis; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases,
disorders and conditions in the area of oncology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area
of gastroenterology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of neurology; Pharmaceutical
and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of gynecology; Pharmaceutical and veterinary products and
preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of urology; Pharmaceutical and veterinary products and preparations, namely, for the treatment
and prevention of diseases, disorders and conditions in the area of cardiology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases,
disorders and conditions in the area of endocrinology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the
area of nephrology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of hematology; Pharmaceutical
and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of allergies; Pharmaceutical and veterinary products and
preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of immunology; Pharmaceutical and veterinary products and preparations, namely, for the
treatment and prevention of diseases, disorders and conditions in the area of psychiatry; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of
diseases, disorders and conditions in the area of anesthesiology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the
area of rheumatology; diagnostic preparations for medical clinical purposes; clinical medical reagents; all of the aforesaid for prescription only
FILING BASIS
SECTION 1(b)
INTERNATIONAL CLASS
042
*IDENTIFICATION
Research and development services for third parties in the field of chemical substances, pharmaceutical and veterinary products and
preparations
FILING BASIS
SECTION 1(b)
ATTORNEY INFORMATION
NAME
Evan A. Raynes
ATTORNEY BAR MEMBERSHIP NUMBER
XXX
YEAR OF ADMISSION
XXXX
U.S. STATE/ COMMONWEALTH/ TERRITORY
XX
FIRM NAME
Symbus Law Group PLLC
STREET
1775 I Street, NW, Suite 1150
CITY
Washington
STATE
District of Columbia
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY
United States
ZIP/POSTAL CODE
20006
PHONE
202-258-0652
EMAIL ADDRESS
eraynes@symbus.com
OTHER APPOINTED ATTORNEY
Symbus Law Group PLLC
CORRESPONDENCE INFORMATION
NAME
Evan A. Raynes
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE
eraynes@symbus.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES)
trademarks@symbus.com; uspto@dockettrak.com
FEE INFORMATION
APPLICATION FILING OPTION
TEAS Standard
NUMBER OF CLASSES
3
APPLICATION FOR REGISTRATION PER CLASS
350
*TOTAL FEES DUE
1050
*TOTAL FEES PAID
1050
SIGNATURE INFORMATION
SIGNATURE
/Evan A. Raynes/
SIGNATORY'S NAME
Evan A. Raynes
SIGNATORY'S POSITION
Attorney of record, DC bar member
SIGNATORY'S PHONE NUMBER
202-258-0652
DATE SIGNED
04/06/2023
SIGNATURE METHOD
Signed directly within the form
PTO- 1478
Approved for use through 10/31/2024. OMB 0651-0009
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number
Trademark/Service Mark Application, Principal Register
Serial Number:97876573
Filing Date:04/06/2023
To the Commissioner for Trademarks:
MARK: BASILEA (stylized and/or with design, see mark)
The literal element of the mark consists of BASILEA. The applicant is not claiming color as a feature of the mark. The mark consists of the word "BASILEA" surrounded by an oval.
The applicant, Basilea Pharmaceutica International AG, Allschwil, a corporation of Switzerland, having an address of
Hegenheimermattweg 167b
Allschwil 4123
Switzerland
XXXX
requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C.
Section 1051 et seq.), as amended, for the following:
International Class 001: Chemical substances for use in the manufacture of pharmaceutical preparations for the treatment of dermatological conditions and for the treatment of infections and
diseases; chemical substances for use in research and development of pharmaceuticals for the treatment of dermatological conditions and for the treatment of infections and diseases; diagnostic
preparations for scientific clinical use; diagnostic reagents for clinical or medical laboratory use
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.
International Class 005: Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of dermatological conditions, namely, eczema, inflammation, infection,
warts, psoriasis, aging of the skin, ultra violet radiation and cancer; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of infections caused by
bacteria, fungi, viruses, and rheumatoid arthritis; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area
of oncology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of gastroenterology; Pharmaceutical
and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of neurology; Pharmaceutical and veterinary products and
preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of gynecology; Pharmaceutical and veterinary products and preparations, namely, for the
treatment and prevention of diseases, disorders and conditions in the area of urology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases,
disorders and conditions in the area of cardiology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area
of endocrinology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of nephrology; Pharmaceutical and
veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of hematology; Pharmaceutical and veterinary products and
preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of allergies; Pharmaceutical and veterinary products and preparations, namely, for the
treatment and prevention of diseases, disorders and conditions in the area of immunology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of
diseases, disorders and conditions in the area of psychiatry; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions
in the area of anesthesiology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of rheumatology; diagnostic
preparations for medical clinical purposes; clinical medical reagents; all of the aforesaid for prescription only
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.
International Class 042: Research and development services for third parties in the field of chemical substances, pharmaceutical and veterinary products and preparations
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.
The owner's/holder's proposed attorney information: Evan A. Raynes. Other appointed attorneys are Symbus Law Group PLLC. Evan A. Raynes of Symbus Law Group PLLC, is a member of the XX bar,
admitted to the bar in XXXX, bar membership no. XXX, and the attorney(s) is located at
1775 I Street, NW, Suite 1150
Washington, District of Columbia 20006
United States
202-258-0652(phone)
eraynes@symbus.com
Evan A. Raynes submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S.
Commonwealth or territory.
The applicant's current Correspondence Information:
Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed,
and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
A fee payment in the amount of $1050 has been submitted with the application, representing payment for 3 class(es).
Declaration
Declaration Signature
Signature: /Evan A. Raynes/ Date: 04/06/2023
Signatory's Name: Evan A. Raynes
Signatory's Position: Attorney of record, DC bar member
Signatory's Phone Number: 202-258-0652
Signature method: Signed directly within the form
Payment Sale Number: 97876573
Payment Accounting Date: 04/06/2023
Serial Number: 97876573
Internet Transmission Date: Thu Apr 06 17:45:05 ET 2023
TEAS Stamp: USPTO/BAS-XXX.XX.XXX.XX-2023040617450743
0500-97876573-86061895471919cf52b64c2252
f1287a6b8beae468d80c7a9b7bf6de45f1374d05
8-CC-45056636-20230406172834630340